# Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist

> **NCT02738151** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 929 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Insulin glargine, 300U/mL
- **DRUG:** Insulin degludec, 100 U/mL
- **DRUG:** Non-insulin anti-diabetic treatment

## Key facts

- **NCT ID:** NCT02738151
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-19
- **Primary completion:** 2017-08-15
- **Final completion:** 2017-08-15
- **Target enrollment:** 929 (ACTUAL)
- **Last updated:** 2018-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02738151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02738151, "Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02738151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*